J.P. Morgan has recently upgraded Corteva (NYSE:CTVA) to an Overweight rating from Neutral, following the company's strategic move to spin off its seed business into a new entity, Vylor (NASDAQ:VYLR). Analysts at J.P. Morgan argue that the remaining segment of Corteva, which focuses on agricultural chemicals, is undervalued and possesses a stronger financial profile than its current market valuation suggests.
The lead analyst, Jeffrey J. Zekauskas, has set a price target of $19 for Corteva by December 2027. This target represents a significant increase from Corteva’s closing price of $12.39 on October 5, indicating a potential upside of approximately 53%. The reduction from J.P. Morgan’s previous target of $83 is attributed to the separation of Corteva’s seed business, rather than a decline in the bank’s evaluation of Corteva's core operations.
Following the spinoff, Corteva is now focused on its crop-chemical operations. According to J.P. Morgan's estimates, this business segment boasts a gross margin of about 38% and EBITDA margins ranging from 16.5% to 17%. Additionally, the company maintains minimal net debt. Currently, Corteva's shares are trading at approximately 5.7 times the projected 2027 EBITDA, which is about one multiple lower than competitor FMC, despite FMC having higher leverage.
Potential for Revaluation
Zekauskas suggests that a high-quality crop-chemicals business typically deserves a valuation of around 10 times the 2027 EBITDA, equating to approximately $21 per share for Corteva, excluding environmental liabilities. However, J.P. Morgan has opted for a more conservative 9-times multiple to arrive at its $19 target.
This conservative valuation reflects uncertainties related to PFAS and PFOA liabilities, which Corteva inherited from the former DuPont structure. J.P. Morgan's model assumes a scenario where combined liabilities for DuPont, Chemours, and Corteva could reach $8 billion, which is double the current $4 billion framework. Under this scenario, Corteva's share of the liability is estimated at about $1.3 billion, or roughly $2 per share.
Cost Reductions and Grain Prices as Catalysts
Corteva has identified opportunities to enhance profitability through restructuring efforts. The company aims to achieve $300 million in run-rate savings from 2024 to 2027 and $500 million by 2029. J.P. Morgan anticipates that some of these savings will result from sourcing active agricultural ingredients from more cost-effective Chinese suppliers.
Another potential catalyst for Corteva is the recovery in grain prices. Corn prices have recently risen to nearly $5 per bushel after experiencing a decline from over $6 to around $4. Higher crop prices can improve the economic conditions for farmers, thereby supporting demand and pricing for agricultural chemicals. J.P. Morgan anticipates the possibility of stable to positive pricing for crop chemicals in 2027, which is not currently factored into its forecasts.
J.P. Morgan projects Corteva's revenue to increase from $7.87 billion in 2026 to $8.10 billion in 2027. Adjusted EBITDA is expected to rise from $1.28 billion to $1.37 billion, while adjusted EPS is projected to grow by 31.6% to 85 cents in 2027. Free cash flow to the firm is anticipated to surge to $542 million from an estimated $63 million this year.
For investors, the positive outlook for Corteva is driven more by the potential revaluation of its relatively unleveraged crop-chemicals business, along with cost savings and improved margins, rather than rapid revenue growth. Key risks include environmental liabilities, potential declines in grain prices, adverse weather conditions, patent expirations, and challenges in achieving planned cost reductions.
In summary, J.P. Morgan's upgrade of Corteva reflects a belief in the company's ability to capitalize on its strengths in the agricultural chemicals sector, while managing potential liabilities and leveraging cost-saving opportunities. The investment bank's analysis suggests that Corteva is well-positioned to deliver value to shareholders through strategic initiatives and market conditions that favor its business model.
Footnotes:
- J.P. Morgan upgraded Corteva to Overweight after the Vylor spinoff. Source.
- Corteva's new price target is $19, indicating a 53% upside. Source.
- Corteva's liabilities from former DuPont structure are estimated at $1.3 billion. Source.
Featured Image: Megapixl @ Tale